IFI16 and inflammatory bowel disease: However, the prolonged barrier disruption with AIM2‐interleukin‐1β secretion may contribute to the chronicity of inflammatory skin lesions.103 Although less explored in other inflammatory diseases, IFI16 also shows higher expression in inflammatory bowel disease, including Crohn's disease and ulcerative colitis.